Jaguar Health Announces Webcast On July 23 To Discuss Phase 3 OnTarget Trial Results For Crofelemer
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health has announced a webcast on July 23 to discuss the Phase 3 OnTarget trial results for Crofelemer. The webcast will also include updates on their cancer supportive care portfolio and the expansion of the Make Cancer Less Shitty (MCLS) program with new ambassadors.
July 23, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health will discuss the Phase 3 OnTarget trial results for Crofelemer and provide updates on their cancer supportive care portfolio during a webcast on July 23. This could positively impact the stock if the trial results are favorable.
The announcement of the Phase 3 trial results for Crofelemer is a significant event for Jaguar Health. Positive results could lead to increased investor confidence and a potential rise in stock price. Additionally, updates on their cancer supportive care portfolio and the expansion of the MCLS program could further enhance the company's market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100